

Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the **August 1, 2021** Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at www.ab.bluecross.ca/dbl/publications.php.

Please refer to the August 1, 2021, updates for complete listings of products available by special authorization, products with changes to criteria for coverage, restricted benefits, products with changes to benefit status, added products, new established interchangeable groupings, products with a price change and discontinued and delisted products.

Please note that the online Interactive Drug Benefit List (iDBL) at www.ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application, and as such, contains the most up-to-date information.

Product supply shortages addressed for ADBL

Alberta Blue Cross has been advised by Actavis Pharma Company that the shortage for Act Dextroamphetamine SR 10 mg Sustained-Release Capsule (DIN 02448319) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **August 9, 2021**. The following grouping was removed from the Critical Supply Product List **July 8, 2021**.

DEXTROAMPHETAMINE SULFATE

10 MG SUSTAINED-RELEASE CAPSULE

00002448319	ACT DEXTROAMPHETAMINE SR	APH	\$ 0.8096
00001924559	DEXEDRINE	PAL	\$ 0.9415

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Travoprost-Timop PQ 0.004%/0.5% Ophthalmic Solution (DIN 02415305) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **August 11, 2021**. The following grouping was removed from the Critical Supply Product List **July 12, 2021**.

TRAVOPROST / TIMOLOL MALEATE

0.004 % / 0.5 % OPHTHALMIC SOLUTION

00002415305	APO-TRAVOPROST-TIMOP PQ	APX	\$ 8.8425
00002278251	DUOTRAV PQ	NOV	\$ 11.3400

continued next page

PHARMACY BENEFACT

continued from previous page

Removal of temporary benefits from the ADBL

Due to the shortage of Ketorolac Tromethamine 30 mg/ml Injection (DIN 02239944) manufactured by Sandoz Canada Inc., Ketorolac Tromethamine 30 mg/ml Injection (DIN 02443376) and Ketorolac Tromethamine 30 mg/ml Injection (DIN 02244947) manufactured by Juno Pharmaceuticals Corp. and Fresenius Kabi Canada respectively, were added as temporary benefits for the ADBL.

Sandoz Canada Inc. has advised Alberta Blue Cross that the shortage of Ketorolac Tromethamine 30 mg/ml Injection (DIN 02239944) has been resolved.

As a result, Ketorolac Tromethamine 30 mg/ml Injection (DIN 02443376) and Ketorolac Tromethamine 30 mg/ml Injection (DIN 02244947) will no longer be considered as temporary benefits for the ADBL after **August 9, 2021**. The above grouping was removed from the Critical Supply Product List **July 9, 2021**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

